1. Scrip
  2. >>Business

Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s

Full Data Presented At CTAD Congress

 
• By Andrew McConaghie

Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.

Roche_Basel
Roche's 'brain shuttle' technology is a promising 'next gen' technology, but for now has missed out while Eisai and Biogen head to market • Source: Image archive

Roche received a major knockback with the failure of Alzheimer’s candidate gantenerumab in a Phase III studies earlier this month, ending a more than decade-long effort to develop the antibody for patients with early signs of the disease, but it is far from giving up on the notoriously tricky field.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.